Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Income (2016 - 2025)

Historic Operating Income for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $51.0 million.

  • Adma Biologics' Operating Income rose 2869.47% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 4536.48%. This contributed to the annual value of $139.0 million for FY2024, which is 54248.8% up from last year.
  • Per Adma Biologics' latest filing, its Operating Income stood at $51.0 million for Q3 2025, which was up 2869.47% from $42.8 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Operating Income peaked at $51.0 million during Q3 2025, and registered a low of -$15.6 million during Q2 2021.
  • In the last 5 years, Adma Biologics' Operating Income had a median value of -$473000.0 in 2023 and averaged $10.1 million.
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 460.91% in 2021, then surged by 838773.78% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Operating Income stood at -$13.2 million in 2021, then soared by 54.07% to -$6.1 million in 2022, then soared by 334.93% to $14.2 million in 2023, then surged by 169.25% to $38.3 million in 2024, then skyrocketed by 33.11% to $51.0 million in 2025.
  • Its Operating Income stands at $51.0 million for Q3 2025, versus $42.8 million for Q2 2025 and $34.9 million for Q1 2025.